Precipio(US:PRPO) Globenewswire·2025-11-14 21:30Financial Performance - Precipio, Inc. reported Q3-2025 revenues of $6.8 million, representing a 30% year-over-year increase from $5.2 million in Q3-2024 and a 20% quarter-over-quarter increase from $5.7 million in Q2-2025 [10] - Adjusted EBITDA for Q3-2025 was $469,000, up $369,000 year-over-year and over $500,000 from Q2-2025, marking a significant turnaround from negative to positive [10] - Operating cash flow improved from a cash burn of $148,000 in Q2-2025 to a positive cash flow of $285,000 in Q3-2025, indicating a $433,000 swing quarter-over-quarter [10] Pathology Services Division - Revenue in the Pathology Services Division increased by approximately $1.0 million, or 20%, from $5.0 million in Q2-2025 to $6.0 million in Q3-2025, driven by new service initiations [3][10] - Gross margins for the Pathology Services Division improved from 43% to 46% quarter-over-quarter, supported by past investments in capacity [7] Products Division - The Products Division saw a revenue increase of 16% quarter-over-quarter, rising from $620,000 in Q2-2025 to $720,000 in Q3-2025, primarily due to existing customers ordering more products [5][10] - Gross margins for the Products Division decreased from 44% in Q2-2025 to 30% in Q3-2025, attributed to investments made to prepare for growth [8] Future Outlook - The company anticipates continued gross margin increases towards the 50% mark as the Pathology business leverages economies of scale and the Products Division builds more revenue [9] - Management expressed confidence in seizing growth opportunities created by the recent financial performance and operational efficiencies [3]